7ACC2: Potent Monocarboxylate Transporter 1 Inhibitor for Cancer Research

Executive Summary: 7ACC2 is a carboxycoumarin derivative that inhibits MCT1 with an IC₅₀ of ~10 nM in SiHa cervical carcinoma cells (source: product_spec). It blocks both extracellular lactate uptake via MCT1 and mitochondrial pyruvate import, exerting dual metabolic inhibition. In vivo, 7ACC2 achieves rapid plasma exposure and delays tumor growth when paired with radiotherapy (source: product_spec). It is a valuable probe for dissecting cancer metabolism and immunometabolic interactions (source: Xiao et al., 2024). APExBIO supplies 7ACC2 (SKU: B4868) for research use.

Biological Rationale

Cancer cells exhibit altered metabolism, relying on aerobic glycolysis and producing excess lactate. Monocarboxylate transporters (MCTs) enable lactate and pyruvate exchange between cells and their microenvironment. MCT1 and MCT4 are highly expressed in tumors, with MCT1 responsible for lactate uptake in oxidative tumor subpopulations (source: product_spec). Disrupting MCT1 function impedes lactate-fueled metabolic flexibility, impairing tumor growth and survival (source: internal_article). Recent immunometabolic research highlights the interplay between metabolic reprogramming and immune evasion, with lactate exchange shaping macrophage phenotype and tumor immune responses (source: Xiao et al., 2024).

Mechanism of Action of 7ACC2

• 7ACC2 is a selective, nanomolar-potency MCT1 inhibitor (IC₅₀ ≈ 10 nM in SiHa cells) (source: product_spec).
• It competitively blocks proton-linked lactate import mediated by MCT1 (source: internal_article).
• 7ACC2 additionally inhibits mitochondrial pyruvate transport, preventing pyruvate entry into the mitochondria (source: internal_article).
• This dual blockade starves tumor cells of key metabolic substrates, disrupting energy production and biosynthetic capacity (source: internal_article).
• MCT1 inhibition by 7ACC2 can also indirectly modulate the tumor microenvironment, potentially altering immune cell polarization and infiltration (source: Xiao et al., 2024).

Evidence & Benchmarks

• 7ACC2 inhibits lactate uptake in SiHa cells with an IC₅₀ of ~10 nM (source: product_spec).
• In vivo, 3 mg/kg (i.p.) dosing in mice reached 4 μM plasma concentration at 10 min, half-life 4.5 h (source: product_spec).
• Repeated 7ACC2 dosing with radiotherapy delayed SiHa xenograft tumor growth significantly compared to controls (source: product_spec).
• 7ACC2 is insoluble in ethanol and water, but solubilizes in DMSO at ≥47.5 mg/mL (source: product_spec).
• MCT1 and MCT4 are preferentially upregulated in tumor cells, supporting targeting strategies (source: Xiao et al., 2024).

Compared to previous reviews, this article provides updated in vivo pharmacokinetic parameters and reinforces dual MCT1/mitochondrial inhibition as a driver of tumor growth delay.

Applications, Limits & Misconceptions

7ACC2 is primarily used in cancer metabolism research as a tool to dissect MCT1-dependent processes. It enables interrogation of lactate- and pyruvate-fueled metabolic adaptation, evaluation of combination therapies (e.g., with radiotherapy), and investigation of metabolic-immune crosstalk (source: internal_article). Recent studies (Xiao et al., 2024) indicate that targeting metabolic checkpoints can synergize with immunotherapies by shifting macrophage phenotype and T cell infiltration.

Common Pitfalls or Misconceptions

• 7ACC2 does not inhibit all MCT family members equally; its primary target is MCT1 (source: product_spec).
• It is not soluble in water or ethanol, necessitating DMSO for stock preparation (source: product_spec).
• Long-term storage of solutions is not recommended due to stability concerns (source: product_spec).
• In vivo efficacy and pharmacokinetics are established only in mouse xenograft models, not in humans (source: product_spec).
• 7ACC2 is intended for research use only; not for diagnostic or therapeutic application in humans (source: product_spec).

Workflow Integration & Parameters

Protocol Parameters

• assay: lactate uptake inhibition | value_with_unit: IC₅₀ ≈ 10 nM | applicability: SiHa cells, in vitro | rationale: enables precise assessment of MCT1 function | source_type: product_spec (link)
• assay: in vivo dosing | value_with_unit: 3 mg/kg i.p. | applicability: mouse xenograft models | rationale: achieves plasma C_max of 4 μM at 10 min, t_1/2 = 4.5 h | source_type: product_spec (link)
• assay: solubility | value_with_unit: ≥47.5 mg/mL in DMSO | applicability: stock solution prep | rationale: maximizes bioavailability for in vitro/in vivo use | source_type: product_spec (link)
• assay: solution storage | value_with_unit: short-term only, -20°C | applicability: all research | rationale: preserves compound stability | source_type: product_spec (link)
• assay: radiotherapy combination | value_with_unit: 7ACC2 + RT | applicability: tumor growth delay in xenografts | rationale: enhances anti-tumor efficacy | source_type: product_spec (link)

Conclusion & Outlook

7ACC2, as supplied by APExBIO, is a validated probe for inhibiting MCT1-mediated lactate uptake and mitochondrial pyruvate import in cancer models. Its dual-action mechanism disrupts metabolic flexibility, delays tumor growth, and provides a platform for exploring metabolic-immune interactions. Integration with emerging immunometabolic strategies, as highlighted by Xiao et al. (2024), positions 7ACC2 as a cornerstone in cancer metabolism research. For complete compound details and ordering, visit the 7ACC2 product page. For complementary perspectives, see this article—which emphasizes 7ACC2’s role in immunometabolic checkpoint discovery, while our article details precise kinetic and workflow data.